Teva jumps as traders position for Q1 results after new biosimilar approval
Teva shares rose about 3% Monday as investors positioned ahead of the company’s Q1 2026 earnings scheduled for April 29. Recent optimism has also been supported by the late-March FDA approval of Teva’s denosumab biosimilar Ponlimsi, expanding its biosimilars growth narrative.
1. What’s moving TEVA today
Teva Pharmaceutical Industries’ U.S.-listed shares traded higher Monday, extending a recent run as markets look ahead to the company’s next quarterly report. Teva is scheduled to report first-quarter 2026 results before the U.S. market opens on Wednesday, April 29, a near-term catalyst that can pull in incremental buying when expectations are for a potentially guidance-moving print. (marketbeat.com)
2. Biosimilars tailwind back in focus
Beyond the calendar-driven earnings setup, investors have recently been re-highlighting Teva’s biosimilars pipeline and commercialization prospects. In late March, the FDA approved Ponlimsi (denosumab-adet), Teva’s biosimilar referencing Amgen’s Prolia, a notable addition to Teva’s biosimilars portfolio that strengthens the company’s longer-term growth narrative as it tries to diversify beyond traditional generics. (tevausa.com)
3. What to watch next
The next major swing factor is Teva’s April 29 earnings report and management commentary on execution across its innovative brands and biosimilars strategy. Traders will focus on any changes to full-year targets, near-term launch cadence, and whether margin and cash-flow trends support continued debt reduction and pipeline investment priorities.